Physician profile
Mark A Peterson
NPI 1407810898
$894.57
in general payments reported to CMS, 2019-2025
17 companies · $154 in 2025
The $154 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.17 · 2020: $64.55 · 2021: $132 · 2022: $240 · 2023: $156 · 2024: $130 · 2025: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $439.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $439.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $392.27 | 2021-2025 | Freestyle Libre 3, Cardiomems |
| Amgen INC. | $192.22 | 2020-2025 | Otezla, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $35.07 | 2024-2025 | Airsupra |
| Merck Sharp & Dohme LLC | $32.57 | 2020-2022 | |
| Lilly USA, LLC | $29.91 | 2024-2025 | Mounjaro |
| Novo Nordisk INC | $29.85 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Otsuka America Pharmaceutical, INC. | $27.52 | 2023 | Rexulti |
| Pfizer INC. | $27.01 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $18.17 | 2019 | |
| Viatris Specialty LLC | $16.50 | 2025 | Yupelri |
| Avanir Pharmaceuticals, INC. | $15.95 | 2020 | |
| Dexcom, INC. | $15.28 | 2025 | Dexcom G6 Transmitter |
| Nevro Corp. | $12.80 | 2023 | Senza |
| Biohaven Pharmaceuticals, INC. | $12.76 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.56 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $12.40 | 2022 | |
| Abbvie INC. | $11.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Peterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.